bionomics pens deal worth up to $us345m

Bionomics pens deal worth up to $US345m by: Cameron England From: AdelaideNow January 05, 2012 9:05AM

BIONOMICS has signed a deal with US drug company Ironwood to develop and commercialise its anti-anxiety drug BNC-210.

Bionomics could receive up to $US345 million in upfront and milestone payments under the deal, and will initially be paid $US3 million.

Another $US10 million may be forthcoming over the next two years.

"The goal of the collaboration is to evaluate the compound's potential as a novel anti- anxiety treatment," Bionomics said in a statement.

"Data from several preclinical studies indicate that BNC210 has anti-anxiety activity without the sedative side effects that are typical of benzodiazepines, a class of drugs used to treat anxiety.

"These data are further strengthened by Phase 1 clinical studies, where pharmacodynamic markers of anti]anxiety activity without sedation were observed in healthy volunteers who took a single dose of BNC210.


End of sidebar. Return to start of sidebar.

"This collaboration furthers both companies'

commitment to develop innovative treatments for patients with high unmet need."

Under the terms of the agreement, the companies will collaborate on initial research and Ironwood will be responsible for worldwide development and commercialisation of all products incorporating BNC210 or other licensed compounds, including funding of clinical trials.